|
Daehan New Pharm launched the non-reimbursed injection ‘Same Injection,’ expanding its presence in the non-reimbursed injection market
2018.06.27
|
|---|
|
Daehan New Pharm is solidifying its market position by consecutively launching non-reimbursed injections this year. Following the release of ‘Collapleo,’ a non-reimbursed injection containing atelocollagen in the first half, the company launched ‘Same injection', a non-reimbursed injection containing SAMe, on the 25th. An anticancer adjunct, ‘Thymosin Injection,’ is also scheduled for future release.
‘Same Injection' contains S-Adenosyl-L-Methionine (SAMe) as its main ingredient, which supports methylation within cells and activates homocysteine metabolism. Methylation is an epigenetic alteration affecting gene expression through chemical changes in the DNA sequence without altering the base sequence itself. Reduced methylation in cells can lead to various conditions: cancer, arteriosclerosis, and aging in adults; ADHD and autism in children; and neural tube defects in fetuses.
Clinical studies have revealed that SAMe activates the TetraHydroBiopterin (BH4) cycle, which increases neurotransmitters serotonin and dopamine, improving depression, and provides strong antioxidant effects that alleviate pain from diseases such as alcoholic liver disease and arthritis.
Many functional medicine and intravenous injection, experts expect ‘Same Injection', with SAMe to aid in the adjunct treatment and prevention of various diseases by acting on diverse and important metabolic mechanisms in the body. Director Ji Young-mi of the Korean Society of Intravenous Therapy (and head of the Seoul St. Mary’s Neurosurgery Functional Medicine Research Center) stated, ‘Same Injection' can provide significant help in the prevention and treatment of many intractable diseases increasing across various age groups in modern society.”
‘Same Injection' is gaining attention across diverse fields ranging from cosmetic surgery, anti-aging, wrinkle improvement, and fatigue relief to adjunctive care for cancer patients, expanding both its prescription scope and market size. According to the Korea Institute for Health and Social Affairs, the market size for non-reimbursed injections has grown rapidly every year since surpassing 1 trillion won.
Alongside previously launched Iscador and Selen Injection, and upcoming Thymosin Injection, ‘Same Injection' is expected to form a key pillar in anticancer adjunctive therapy.
Daehan New Pharm has ambitious plans to revamp the intravenous injection market by promoting ‘Same Injection' aggressively through online and offline channels in the second half of the year, aiming to grow it into a major pillar of their injection business. |


Home